Illumina collaborates with National Cancer Center Japan

By The Science Advisory Board staff writers

January 25, 2022 -- Illumina and National Cancer Center Japan are collaborating on an international joint research project that will use Illumina's high-throughput DNA sequencing to analyze the blood-based genomic profile and clinical information of patients living with nasopharyngeal carcinoma.

The study will be part of the Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN). One of the main research areas of A-TRAIN is nasopharyngeal carcinoma.

The study will be conducted as part of an international collaborative study under the Asian Clinical Trials Network for Cancers project, which aims to accelerate the implementation of clinical research and develop personalized treatments. The overall project includes research involving patients with cervical cancer, ovarian cancer, ovarian clear cell carcinoma, nasopharyngeal carcinoma, endometrial cancer, and breast cancer.

In the joint study to be conducted by Illumina and National Cancer Center Japan, genomic analysis of blood samples of up to 96 patients with nasopharyngeal cancer will be analyzed using Illumina's TruSight Oncology 500 circulating tumor DNA. A database will be constructed and analyzed by examining genomic abnormalities by liquid biopsy in addition to clinical information, such as treatment details and prognosis.

The resulting data will be used by the Japan-led initiative to establish a platform for international collaborative trials with Malaysia, Thailand, the Philippines, Indonesia, and Vietnam, which are actively promoting cancer treatment development in the southeastern Asian region.

No financial details of the collaboration were disclosed.

Illumina delivers results, growth plans at JP Morgan Healthcare Conference
Illumina's CEO, Francis deSouza, discussed the company's growth trajectory, including 2021 results and 2022 guidance at the 2022 virtual J.P Morgan Healthcare...
Illumina partners with SomaLogic for proteomics assay
Illumina has entered into a definitive co-development agreement with SomaLogic to bring the SomaScan proteomics assay to Illumina's current and future...
Gretel, Illumina partner to develop synthetic data for genomic research
Gretel announced a collaboration with Illumina to create synthetic genomic data that can be accessed by medical researchers globally. The companies also...
Illumina supports Norway's pioneering precision medicine study
Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling in...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter